Incyte stock plummets following disappointing clinical study results

Incyte Corp. ’s stock price plunged nearly 20 percent Friday after the Wilmington biotechnology company announced disappointing late-stage study results for an experimental cancer therapy. The results from a phase-III clinical study, testing Incyte’s new drug candidate epacadostat with Merck&Co. Inc. ’s immunotherapy drug Keytruda, found the combination therapy did not improve progression-free survival in patients with metastatic melanoma, a type of skin cancer. Incyte and Merck said, at…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news

Related Links:

Abstract Significant progress has been made in cancer immunotherapy with checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)-programmed death-ligand 1 signaling pathways. Tumors from patients showing sustained treatment response predominately demonstrate a T cell-inflamed tumor microenvironment prior to, or early on treatment. Not all tumors with this phenotype respond however and one mediator of immunosuppression in T cell-inflamed tumors is the tryptophan-kynurenine-aryl hydrocarbon receptor (Trp-Kyn-AhR) pathway. Multiple mechanisms of immunosuppression may be mediated by this pathway includi...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Abstract The field of cancer immunology stepped into the limelight this year when James P. Allison and Tasuku Honjo received the Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation. Among many exciting advances contributing to the coming of age of tumour immunology as a viable clinical specialty has been the ability to progress from the initial elucidation of tumour antigens, such as the melanoma antigen, MAGE-1, to high-throughput sequencing facilitating identification of T cell epitopes from diverse tumour neoantigens. This has resulted from the...
Source: Immunology - Category: Allergy & Immunology Authors: Tags: Immunology Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: These results support the clinical use of consensus MAGE-A immunogens with the capacity to target multiple MAGE-A family members to prevent tumor immune escape. PMID: 30262507 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
LOS ANGELES– Stand Up To Cancer (SU2C), a division of the Entertainment Industry Foundation (EIF), is proud to announce that the Hollywood community is rallying together yet again to support the sixth biennial televised fundraising special. CBS will donate one hour of commercial-free primetime to broadcast the event on Friday, Sept. 7  from 8:00 – 9:00 PM ET/PT (7:00 – 8:00 PM CT). Mahershala Ali, Kathy Bates, Katie Couric, Jennifer Garner, Tony Hale, Marg Helgenberger, Ed Helms, Ken Jeong, Marlee Matlin, Matthew McConaughey, Maria Menounos, Jillian Michaels, Trevor Noah, Dak Prescott, Italia Ricci, ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Only CBS Stand Up To Cancer Source Type: news
Publication date: Available online 30 April 2018Source: Seminars in Cancer BiologyAuthor(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. EbertAbstractImmunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhi...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusions: Early favorable signs of FDG-PET parameters may vary among diseases with immune checkpoint inhibitors. Mean FDG uptake was elevated in several immune-related organs at the early restaging scan. Among them, elevated FDG accumulation in thyroid might be a candidate sign of monitoring effectiveness of immunotherapy observed earlier than immune-related lymphadenopathy. Relationship between % change () of PET parameters and patients outcome% chage (Î") of PET parametersMalignant melanoma(Odds, 95%CI, p)Malignant lymphoma (Odds, 95%CI, p)Renal cell carcinoma (Odds, 95%CI, p)Î&quo...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Other Solid Tumors Source Type: research
Publication date: Available online 30 April 2018 Source:Seminars in Cancer Biology Author(s): Tobias Gutting, Elke Burgermeister, Nicolai Härtel, Matthias P. Ebert Immunotherapy is the latest revolution in cancer therapy. It continues to show impressive results in malignancies like melanoma and others. At least so far, effects are modest in colorectal cancer (CRC) and only a subset of patients benefits from already approved checkpoint inhibitors. In this review, we discuss major hurdles of immunotherapy like the immunosuppressive niche and low immunogenicity of CRC next to current achievements of checkpoint inhibitor...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
FINDINGSMelanoma, a relatively rare but deadly skin cancer, has been shown to switch differentiation states — that is, to regress to an earlier stage of development — which can lead it to become resistant to treatment. Now, UCLA researchers have found that melanomas can be divided into four distinct subtypes according to their stages of differentiation. Cell subtypes that de-differentiated — meaning that they reverted back to a less-mature cell — showed sensitivity to a type of self-inflicted cell death called ferroptosis.The research also showed that certain subtypes of melanoma cells could be succ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
SummaryImmunotherapies comprise of a  class of cancer therapies that are increasingly used for treatment of several cancer entities. Active immunotherapies encompassing immune checkpoint inhibitors are the most widespread class of immunotherapies, with indications for melanoma, non-small lung cancer, renal cell carcinoma, urothelial c arcinoma, head and neck squamous cell carcinoma, and Hodgkin’s lymphoma. Immune checkpoint inhibitors have demonstrated unique response patterns that are not adequately captured by traditional response criteria such das the Response Evaluation Criteria in Solid Tumors (RECIST) and ...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Health Management | Immunotherapy | Melanoma | Merck | Skin | Skin Cancer | Study